今天（26日）是第38个国际禁毒日，关注青少年身边的"隐形杀手"。 2021年国家药品监督管理局发布的《国家药物滥用监测年度报告》显示，非管制类药物滥用人数逐年增多，其中未成年滥用情况尤为严重。 前不久，国家禁毒办发布的《2024年中国毒情形势报告》指出，国内滥用物质种类发生结构性变化， ·麻精药品和未列管成瘾性物质滥用快速蔓延， ·滥用人数不断增多， ·青少年滥用问题突出。 2024年查处35岁以下滥用人数7.6万人次，占查获滥用麻精药品总人数的86.4%。 尽管此前有媒体报道过青少年药物滥用的问题，但这种现象并没有消失，严重侵蚀青少年的身心健康。哪些药物滥用会成为毒品？如何流入青少年手中？为 何青少年药物滥用屡禁不止？严打青少年身边"隐形杀手"如何筑牢全民禁毒防线？ 警方破获利用外卖平台非法贩卖右美沙芬案 哪些药物滥用会成为毒品？《2024年中国毒情形势报告》显示，滥用美托咪酯、复方曲马多、右美沙芬等人数较多。 以右美沙芬为例，它是用于临床镇咳的药品，常规剂量下可以起到止咳作用，但它同时也是吗啡类衍生物，在2024年7月1日被我国列入第二类精神药品进行 列管。这些麻精药品如果用于治疗疾病，在医生的指导下使 ...

充分发挥以工代赈实效 以工代赈是稳就业稳经济政策工具之一。近日，国家发展改革委联合有关部门印发《以工代赈加力扩围 促进重点群体就业增收行动方案》。这项增量政策如何进一步加大对困难群体帮扶力度？ 当前，外部环境的复杂性、严峻性、不确定性有所增加，中国经济走势怎么看？稳就业稳经济推动高质 量发展若干举措落实情况如何？夏季正值全年用电负荷高峰，能源保供形势怎么样？ 6月26日，国家发展改革委举行新闻发布会，有关负责人介绍了相关情况并答记者问。 国际投行上调中国经济预测 "今年以来，面对更趋复杂严峻的外部环境，我们坚持稳中求进、以进促稳，实施更加积极有为的宏观 政策，加快落实稳就业稳经济推动高质量发展若干举措，经济运行总体平稳。"国家发展改革委政策研 究室副主任李超在会上表示。 从供给看，农业生产有序开展，工业服务业稳定增长。眼下，"三夏"工作有序推进。5月份，规模以上 工业增加值同比增长5.8%，服务业生产指数增长6.2%，增速比上月提高0.2个百分点。 从需求看，消费投资持续扩大，出口保持较快增长。5月份，社会消费品零售总额同比增长6.4%，增速 是2024年以来最高水平。前5个月，固定资产投资稳定增长，其中制造 ...

r - 2016 - 12 1322 1 電子数値 (1) 1 (1) 1 (1) 1 (1) 1 (1) 1 ) 1 (1) 1 ) 1 (1) 1 ) 1 (1) 金十图示：2025年06月26日（周四）华尔街恐惧与贪婪指数（美盘后） @ JIN10.COM O.COM 金十数据 | 一个交易工具 ...

金融知识触手可及 在经济快速发展的当下，金融安全是保障人民群众财产安全和维护社会稳定的重要基石，践行新时 代"枫桥经验"，邮储银行北京分行以"矛盾预防在源头，风险化解在基层"为指引，于2025年6月组织开 展"防范非法金融活动宣传月"主题活动，多举措提升群众风险防范意识，全力推进金融风险"早识别、 早预警、早暴露、早处置"，为民众"钱袋子"和幸福生活保驾护航。 扎根基层广宣传 警银协作强本领 筑牢金融安全堡垒 以"守住钱袋子·护好幸福家"为主题，邮储银行北京分行在宣传月里深入推进网点宣传工作。邮储银行 北京分行将揭露非法金融活动作案手法和风险识别方式作为宣传重点内容，提升广大民众的风险识别能 力；采用"身边人讲身边事""以案说法"等贴近民众的解说方式，让"天上不会掉馅饼""高收益意味着高 风险"等投资理财知识深入人心，帮助大众树立理性投资理财、远离非法金融活动、依法维护合法权益 的理念。同时，大力宣传《防范和处置非法集资条例》《北京市地方金融监督管理条例》等法律法规， 宣传行政处罚、刑事打击典型案件和各类受惩戒的真实案例，以正反面案例相结合的方式进行普法教 育。 提升银行员工防范非法金融活动的能力，有利于更好 ...

Company Overview - Yorkville Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aimed at effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [5] - The company has not selected any specific business combination target and has not engaged in substantive discussions with any potential targets [5] - The company intends to focus its search for business combinations at the intersection of media, technology, and entertainment [5] Initial Public Offering (IPO) Details - The company announced the pricing of its initial public offering of 15,000,000 units at $10.00 per unit, with units expected to be listed on Nasdaq under the ticker symbol "YORKU" starting June 27, 2025 [1] - Each unit consists of one Class A ordinary share and one-third of one redeemable warrant, with each whole warrant allowing the holder to purchase one Class A ordinary share at a price of $11.50 per share [1] - The offering is expected to close on June 30, 2025, subject to customary closing conditions [1] - The underwriter has a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments [1] Legal and Management Information - Clear Street is acting as the sole book-running manager for the offering, with D. Boral Capital LLC as co-manager [2] - Legal counsel for the company includes DLA Piper LLP (US) and Maples and Calder (Cayman LLP) [2] - A registration statement on Form S-1 relating to the securities sold in the IPO has been filed with the SEC and was declared effective on June 26, 2025 [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended May 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41984 Black Hawk Acquisition Corporation (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or other jurisdicti ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarter ended May 31, 2025 FORM 10-Q (MARK ONE) (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4125 Blackhawk Plaza Circle, Suite 166 Danville, CA 94506 (Address of principal executive offices) ☐ TRANSITION REPORT P ...

周四（6月26日）纽约尾盘，CME比特币期货BTC主力合约较周三纽约尾盘跌0.12%，报10.8万美元。 CME以太币期货DCR主力合约涨0.12%，报2444.50美元。 ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Digimarc Corporation regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 3, 2024, to February 26, 2025 [3]. - Allegations include that Digimarc's management made materially false and misleading statements, specifically regarding: 1. A significant commercial partner's decision not to renew a large contract on the same terms. 2. The need for Digimarc to renegotiate this large commercial contract. 3. The adverse impact on the company's subscription revenue and annual recurring revenue due to the renegotiation. 4. Misleading positive statements about the company's business and prospects as a result of the above issues [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 7, 2025, to participate in the case without any cost or obligation [4]. - Upon registration, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading statements regarding the safety and clinical trial protocol of its RP-A501 treatment, which resulted in significant stock price decline after the FDA placed a clinical hold on the study following a Serious Adverse Event [3][4]. Summary by Relevant Sections Allegations - The complaint alleges that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol, including the risk of Serious Adverse Events (SAEs) and participant deaths [3]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, leading to artificially inflated stock prices [3]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a patient's death linked to the trial, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [3]. Class Action Details - The class period for the lawsuit is from February 27, 2025, to May 26, 2025, with a deadline for shareholders to register as lead plaintiffs by August 11, 2025 [4]. - Shareholders who register will receive updates on the case's progress through portfolio monitoring software [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, seeking recovery for losses incurred due to misleading statements by companies [5].